Fabrication of flexible composite drug films via foldable linkages using electrohydrodynamic printing by Wu, Shuting et al.
1 
 
Fabrication of Flexible Composite Drug Films via Foldable Linkages 1 
Using Electrohydrodynamic Printing  2 
 3 
Shuting Wua,b, Zeeshan Ahmadc, Jing-Song Lia, Ming-Wei Chang a,b, d* 4 
 5 
a Department of Biomedical Engineering, Key Laboratory of Ministry of Education, 6 
Zhejiang University, Hangzhou 310027, P.R. China. 7 
b Zhejiang Provincial Key Laboratory of Cardio-Cerebral Vascular Detection 8 
Technology and Medicinal Effectiveness Appraisal, Zhejiang University, Hangzhou 9 
310027, P.R. China. 10 
c Leicester School of Pharmacy, De Montfort University, The Gateway, Leicester, LE1 11 
9BH, UK. 12 
d Nanotechnology and Integrated Bioengineering Centre, University of Ulster, 13 
Jordanstown Campus, Newtownabbey, BT37 0QB, Northern Ireland, UK. 14 
 15 
* Corresponding author:  Ming-Wei Chang, Ph.D.,  16 










The simple method to manufacture a flexible multi-drug with hydrophilic and 2 
hydrophobic molecules-loaded composite membrane via three dimensional (3D) 3 
electrohydrodynamic (EHD) printing has been demonstrated in this study. The 4 
composite membrane consists of two different drug-loaded sections: cellulose acetate-5 
ibuprofen (CA-IBU) and cellulose acetate-paracetamol (CA-Para), respectively, with 6 
an intermediate polycaprolactone (PCL) folding component. The composite 7 
membranes can be folded and housed in commercial capsules to aid swallowing. By 8 
changing the number of PCL layers in the intermediate layers, it is possible to control 9 
and modify the mechanical and unfolding properties of the composite membrane. IBU 10 
and Para are loaded into the CA polymeric matrix in their amorphous states, with the 11 
matrices exhibiting Higuchi and first order release kinetics, respectively. The 12 
combination of IBU and Para can potentially be used as analgesic for patients. Magnetic 13 
nanoparticles as a functional material can be incorporated into the PCL matrix for wide 14 
targeting and traceable applications. The composite membrane here possesses good 15 
biocompatibility and flexibility; enabling extensive application prospects in drug 16 
combination therapy and personalized medicine.   17 
 18 












1. Introduction 1 
Dosage forms administered orally (e.g. tablets, capsules, liquids) are the preferred 2 
method of giving medication and are known for patient compliance and safety [1, 2]. 3 
Despite this, limitations with respect to controlling drug release and personalizing  4 
dosing regimen remain [3]. To circumvent this several strategies have been developed 5 
including novel capsule designs (and their manufacturing) which display improved 6 
behavior in the gastrointestinal tract [4, 5]. In addition, multi-functional drug delivery 7 
devices or technologies are now coming to the fore to address challenges posed for 8 
combination therapy (e.g. for cancer and angiocardiopathy [6, 7]. Recent advances have 9 
shown that both hydrophilic and hydrophobic drugs can be incorporated in a single 10 
dosage and used in synergy to achieve comprehensive therapeutic effects [8]. 11 
Three dimensional (3D) electrohydrodynamic (EHD) printing is an ambient 12 
environment,  non-conventional, one-step process used to prepare 3D microstructures 13 
via pre-programmed collector movements [9]. Under optimal applied voltage, the 14 
electrified jet undergoes rapid stretching and solidification before reaching the 15 
collector. The controlled deposition of fibers is achieved by reducing the distance 16 
between nozzle and collector [10]. A variety of materials can be and have been 17 
processed to develop pharmaceutical drug carriers via this technique [11]. Compared 18 
to other 3D printing techniques (e.g. fused deposition modelling and selective laser 19 
sintering), 3D EHD printing provides a processing environment suitable for less 20 
thermal stable drugs and the ability to control the process easily and precisely [12, 13]. 21 
Moreover, mesh-structure patterning can be used to control surface hydrophobicity and 22 
thus drug release [14, 15]. 23 
 Many polymers such as polyvinyl alcohol (PVA), polycaprolactone (PCL) and 24 
cellulose acetate (CA) have been used as drug carrier or matrix materials for drug 25 
dosage formulations [16-18]. PCL is a biocompatible polymer with good mechanical 26 
properties, which has been applied for various applications requiring strength, such as 27 
surgical sutures, wound dressings and filtration [19-21]. Cellulose acetate (CA) is 28 
generally prepared through an esterification reaction of cellulose with acetic anhydrides 29 
[22]. Due to the biodegradability, hydrophillic nature and excellent stability of CA, it 30 
has been widely used for many bio-interfacing applications [23-25], as drug 31 
encapsulating matrices, and for drug delivery applications [26]. 32 
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In recent years, research has been directed towards improving comfort for patients with 1 
respect to pain when administrating treatment. Based on this, drug combination 2 
therapies have been put forward with the superiority of better analgesic effect when 3 
compared to monotherapy [27], whilst improving patient compliance and convenience 4 
[28]. Ibuprofen (IBU) is a widely used non-steroidal anti-inflammatory drug (NSAID) 5 
with very little side effects, which is used to treat pain and inflammation [29]. 6 
Paracetamol (Para) is prescribed as an analgesic and antipyretic with good tolerance 7 
and safety [30]. Both IBU and Para are used for pain relief after surgery [31]. It has 8 
been proved that the combination of IBU and Para can provide a significantly more 9 
effective treatment of acute pain than monotherapies [32]. 10 
In this study, we demonstrate the engineering of a flexible multi-drug dosage membrane 11 
hosting both hydrophilic and hydrophobic molecules via three dimensional (3D) 12 
electrohydrodynamic (EHD) printing. The flexible composite film comprises foldable 13 
linkages and the unfolding process enables increased surface area for expedited drug 14 
release and increasing retention time which is ideal to reduce dosing. Moreover, loading 15 
into different compartments of the composite membrane is a proof-of-concept for 16 
combinatorial therapy which is shown via precision 3D printing. The flexible composite 17 
membrane with one central component can be folded and enclosed into capsules for 18 
oral administration. Composite membranes with different thickness have been 19 
fabricated by altering the number of layers of the central components (5, 10 and 20 20 
layers, respectively) to investigate the impacts of the central component layer numbers 21 
on the mechanical property and unfolding property of the composite membranes and to 22 
find the relatively best parameter. Also, the unfolding process is crucial in terms of 23 
expansion potential which is useful for the current application as it can increase the 24 
surface area of printed membranes and also prolong retention time in the 25 
gastrointestinal tract. IBU and Para were loaded into different regions of the composite 26 
membrane and were selected as model drugs to show proof-of-concept for 27 
combinatorial therapy and to enable multiple drug release behavior for personalized 28 
medicine. Magnetic nanoparticles were added into the central PCL component for 29 
potential targeting applications.  30 
 31 
2. Materials and Methods 32 
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2.1. Materials 1 
Cellulose acetate (CA, Mw = 30000 g/mol), polycaprolactone (PCL, Mw = 80000 g/mol) 2 
and ibuprofen (IBU, ≥98%) were all obtained from Sigma-Aldrich, USA. Paracetamol 3 
(Para, ≥ 99%) were purchased from Aladdin, China. Acetone, N, N-4 
Dimethylformamide (DMF), acetic acid and phosphate buffer saline (PBS, pH= 7.4) 5 
were all obtained from Sinopharm Chemical Reagent, China. Magnetic nanoparticles 6 
(Fe3O4 NPs) were supplied by HWRK Chem, China. Deionized water (DI water) was 7 
prepared in-house (Millipore Milli-Q Reference ultra-pure water purifier, USA). 8 
Minimum Eagle’s medium (MEM, Gibco) and fetal bovine serum (FBS) were obtained 9 
from Invitrogen, USA. All chemicals used were of analytical grade.  10 
2.2. Preparation of 3D EHD printing solutions 11 
Acetone and DMF (acetone:DMF=1:1, v/v) were used to dissolve CA at the 12 
concentration of 22% (w/w) by mechanical stirring (VELP ARE heating magnetic 13 
stirrer, Italy) for 5 hours. IBU (5% w/w of CA) and Para (4% w/w of CA) were then 14 
added to the CA solution, respectively, and dissolved by mechanical stirring for 2 hours 15 
to obtain homogenous IBU-loaded CA solution and Para-loaded CA solution. The drug 16 
concentration of IBU and Para were altered to demonstrate practical feasibility of 17 
personalization and drug loading capabilities for co-therapy.  18 
PCL was dissolved in acetic acid at a concentration of 24 %w/w under mechanical 19 
stirring (VELP ARE heating magnetic stirrer, Italy) for 6 hours at room temperature. 20 
Fe3O4 NPs were added to the PCL solution at a concentration of 0.5 %w/w, which was 21 
dispersed through bath sonication for 2 hours to yield a homogeneous suspension. 22 
2.3. Preparation of composite membrane 23 
The 3D EHD printing set-up was shown in Fig. 1, including a stainless steel nozzle 24 
(outer diameter = 0.9mm, inner diameters = 0.7 mm), a syringe pump (KD Scientific 25 
KDS100, USA), a high voltage power supply (Glassman high voltage Inc. series FC, 26 
USA) and a controllable X-Y-Z movement stage. Firstly, the 5 ml syringe was loaded 27 
with drug solutions and infused through the printing nozzle at a flow rate of 0.3 ml/h. 28 
The path of movement stage was pre-designed and programmed (Adtech, China) in a 29 
grid pattern. Under the optimum preparation parameters (applied voltage of 2 kV, 30 
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nozzle-to-collector distance of 2 mm and movement stage speed of 100 mm/s), well 1 
aligned drug-loaded films with grid shapes were fabricated (6.5 × 13 mm) within 5 min. 2 
The layer number of the drug-loaded films were set as 10 layers.  3 
 The CA-IBU film and CA-Para film were then linked by the PCL fibrous central 4 
component to obtain a flexible, composite membrane. The distance between CA-IBU 5 
and CA-Para films was 2 mm. The printing parameters of the central component was 6 
optimized to achieve a stable printing Taylor cone. The applied voltage and nozzle-to-7 
collector distance were set to 2 kV and 3 mm, respectively. The flow rate of PCL 8 
solution was 0.2 ml/h and the speed of the movement stage was 40 mm/s. The layer 9 
number of the central component was set to 5, 10 and 20 layers, respectively (denoted 10 
as P5, P10 and P20). 11 
2.4. Mechanical characterization 12 
The mechanical characterization of tension was investigated using a universal material 13 
testing machine (Zwick/Roell Z020, Zwick, Germany). The sizes of P5, P10 and P20 14 
were all 13.5 × 15 mm and the thickness of the central components were approximately 15 
40 µm, 70 µm and 140 µm, respectively. Each specimen was fixed by the grips and then 16 
tensioned at a rate of 10 mm/min until the composite membranes fractured. Each 17 
sample was performed in triplicate. 18 
2.5. Unfolding property test 19 
The unfolding property of the composite membranes was tested in vitro. Each 20 
composite membrane was folded and encased in empty capsules (size 0). The composite 21 
membrane-loaded capsules were then placed into a 100 ml beaker, containing 60 ml 22 
PBS (37 °C). After being left to stand for 15 minutes, the unfolding angles of composite 23 
membranes with different folding-part layers were measured using ImageJ software 24 
(version 1.48, National Institute of Health, USA). The same test but placed in a HZ-25 
8801K thermostatic oscillator (Taicang Science and Education Factory, China) was 26 
also performed and analyzed. 27 
2.6. Fourier transform infrared (FTIR) spectroscopy 28 
The spectra of CA, Para, PCL and the composite membrane were analyzed by Fourier 29 
transform infrared spectroscopy (FTIR, IR Affinity 1, Shimadzu, Japan). For each test 30 
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disk, 3 mg sample was mixed with 300 mg KBr powders and then pressed into a 1 
transparent disk. The disks were then used for FTIR analysis between 400 and 4800 2 
cm-1 and the resolution was set as 4 cm-1. 3 
2.7. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) 4 
Thermal analysis was performed using differential scanning calorimetry (DSC) (PE 5 
DSC 7, Perkin-Elmer, USA). Samples (~3 mg) were heated over a temperature range 6 
of 30 to 260 °C, at a heating rate of 10 °C/min in the N2 environment. 7 
XRD analysis of each sample was performed by X-ray crystal diffractometer (Gemini 8 
A Ohra, Oxford, UK). The printed membrane was cut into pieces and then sent to XRD 9 
test center for analysis. The scan range of 2 theta was between 5 ° and 60 ° at a step 10 
size of 0.02 °. The voltage and intensity were 40 kV and 40 mA. 11 
2.8. In vitro drug release 12 
HCl solution (36.46 g/mol) and phosphate buffered saline (PBS, pH=7.4) were used to 13 
prepare simulated gastric fluid (SGF, pH=1.7) and simulated intestinal fluid (SIF, 14 
pH=7.4), respectively. Drug release tests were performed using a HZ-8801K 15 
thermostatic oscillator (Taicang Science and Education Factory, China) at 50 rpm and 16 
at the ambient temperature of 37 ±0.5 °C. The tests were first performed in 20 ml SGF 17 
for 2 hours and then in 20 ml SIF for 6 hours. The characteristic UV peaks of IBU and 18 
Para were 222 nm and 243 nm, respectively (UV-2600 spectrophotometer, Shimadzu, 19 
Japan). At time intervals, 3 ml of the release solution was extracted for UV analysis, 20 
and then same volume of fresh medium was supplied to the release solution. Each 21 
sample was tested in triplicate. The cumulative drug release percentage can be 22 
estimated as Equation 1 [18].  23 
Drug	release	 % = ,-
,.
×100%                                                           (1) 24 
Where Ct is the drug release in the solution at time t and CM is the total drug release in 25 
the solution. 26 
The drug encapsulation efficiency (EE) can be calculated as Equation 2 [33]. 27 
EE	 % = 345678	59	:;6<	=7>?@A6B?8=:	C7	4=4D;?7=A
EF=5;=8C>?B	?45678	59		:;6<
×100%       (2) 28 
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The drug loading capacity (LC) can be obtained using Equation 3 [34]. 1 
LC	 % = 345678	59	:;6<	=7>?@A6B?8=:	C7	4=4D;?7=A
I=C<F8	59	8F=	4=4D;?7=
×100%   (3) 2 
2.9 Kinetics of drug release 3 
The drug release mechanisms of IBU and Para from composite membranes were 4 
analyzed by fitting release data to zero-order, first-order, Higuchi and Korsmayer–5 
Peppas mathematic models [14, 35]. The best fit model for drug release can be 6 
determined by comparing the correlation coefficient (R2).  7 
2.10. Scanning electron microscopy (SEM) characterization 8 
Scanning electron microscopy (SEM, Eindhoven, Netherlands) was used to investigate 9 
the morphology of the composite membranes. Each Sample was sputter-coated with 10 
gold for 90 s before the observation. The accelerating voltage was set as 10 kV. ImageJ 11 
software (National Institute of Health, USA) was used to determine the diameters of 12 
the printed fibers. The diameter distribution diagrams were obtained by Origin software 13 
(version 8.0, Originlab, USA). 14 
2.11. Magnetic test 15 
The magnetic property of the printed composite membrane was investigated using a 16 
vibration sample magnetometer (VSM Mini-CFM measurement system, Cryogenic 17 
Ltd., UK) at 300 K. Composite membrane with a known weight was placed in the 18 
magnetometer and measured in a range of -10000 Oe to 10000 Oe. 19 
2.12. Cell culture 20 
In order to analyze the biocompatibility of the printed composite membrane, L929 21 
mouse fibroblast cells were cultured on the composite membrane with MEM medium 22 
containing 1% antibiotic-antimycotic and 10% FBS in a 6 cm diameter culture dish at 23 
37 °C, under 5% CO2 environment.  24 
After 3 days incubation, cells were fixed with 4 (v/v) % formalin for 30 min and then 25 
permeabilized by 0.1% Triton X-100 for 5 min. After being washed three times with 26 
PBS, Alexar Fluor 546 phalloidin (1:200 v/v of phalloidin:PBS, Invitrogen, USA) were 27 
used to stain the cell cytoskeleton for 20 min followed by triple PBS rinses. 4′, 6′-28 
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diamidino-2-phenylindole hydrochloride (DAPI, 1:5000 v/v of DAPI:PBS, Invitrogen, 1 
USA) was then used to stain the cell nuclei for 5 min followed by PBS rinses two times. 2 
The cell distribution on the composite membrane was observed by a fluorescent 3 
microscope (Nikon Ti-S, Japan). 4 
 5 
3. Results and Discussion 6 
3.1. Preparation and characterization of composite membranes 7 
The printed composite membranes and their capsules are shown in Fig. 2. The 8 
composite membranes demonstrated grid structure as a result of the pre-determined 9 
patterns. The central component (PCL) provides flexability; allowing the composite 10 
membrane to fold and thus allowing the composite membranes to be enclosed in size 0 11 
capsules for oral administration. To investigate the effect of the central component layer 12 
numbers on mechanical properties and unfolding properties, composite membranes 13 
with 5 layers, 10 layers and 20 layers of intermediate PCL component, respectively, 14 
were printed and denoted as P5, P10 and P20 accordingly, and the mean weights were 15 
measured to be 3.2 ± 0.1, 3.6 ± 0.2 and  4.2 ± 0.1 mg, respectively. 16 
The tensile stress-strain curves of the composite membranes with different folding 17 
layers (P5, P10 and P20) are shown in Fig. 3a. It can be seen that the stress-strain curve 18 
of P5 was typical for fiber tension exhibiting three characteristic stages including a 19 
linear elastic section (region A), a progressive deformation section (region B) and a 20 
failure section (region C) [36]. It has been proven that thickness of the fibrous mats 21 
affects the its strength [37]. The tensile stress-strain curve of P10 was similar to that of 22 
P5 with three characteristic stages. However, here there was a much larger maximum 23 
stress due to the increased number of layers of PCL in P10.  24 
The stress-strain curve of P20 showed very different results. An arrow-like pattern with 25 
a much smaller elongation was found. During the tension process of P20, the fiber 26 
breakage happened on the joint between the drug-loaded sectors and the folding sector, 27 
as the insert in Fig. 3a shows.  28 
As shown in Fig. 3b, as the layer number of the central component increased, the 29 
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maximum stress of the composite membrane increased from 0.47 ± 0.01 Mpa to 1.52 ± 1 
0.20 MPa, while the maximum strain of the composite membrane decreased from 182 2 
± 35% to 15 ± 3%. The elastic moduli of P5, P10 and P20 are calculated to be 0.07, 3 
0.36 and 0.72 Mpa, respectively. It is evident that the number of PCL layers plays an 4 
important role in the mechanical properties of the composite membranes. The good 5 
mechanical property is beneficial for the unfolding property and resisting destruction 6 
ability of composite membranes. 7 
To investigate the impact of the central component layer numbers on the unfolding 8 
properties, unfolding tests of the composite membranes (P5, P10 and P20) were 9 
performed with the unfolding angle data being depicted as shown in Fig. 4. After 15 10 
minutes’ standing, the capsule shells dissolved, and the folded composite membranes 11 
re-spread out as the inserts of Fig. 4a shows. The unfolding angles of P5, P10 and P20 12 
were calculated to be 44.2 ± 5.8°, 116.0 ± 5.4° and 145.2 ± 2.2°, respectively. This 13 
indicates that the unfolding properties of the composite membranes improved with the 14 
increase of the central component layer numbers. The results of the similar unfolding 15 
test placed in a HZ-8801K thermostatic oscillator for 15 minutes, showed the same 16 
varying tendency that the unfolding angles changed from 92.2 ± 7.4° to 148.7 ± 18.3°, 17 
as the central component layer number increased from 5 layers to 10 layers. In addition, 18 
the unfolding angles of composite membranes with oscillation were larger than those 19 
without oscillation, especially P5 which was due to the smaller residual strain and better 20 
flexibility. This indicates that oscillation can facilitate the unfolding process of the 21 
composite membranes. Taking into consideration of the mechanical properties and 22 
unfolding properties as well as the preparation process, P10 was selected as a sample 23 
for subsequent studies. 24 
The SEM images of three all 3 sectors in the composite membrane are shown in Fig. 5. 25 
Fig. 5a shows the micrograph of the central component with a grid structure. The 26 
diameter distribution of the PCL fibers is between 4 µm to 19 µm, and the mean 27 
diameter of PCL fibers is 10.5 ± 3.2 µm. Fig. 5a’ depicts a detailed image of a PCL 28 
fiber, showing the precise stack of the printed PCL fibers with 10 layers. The SEM 29 
images of the CA-Para sector and CA-IBU sector of the composite membrane are 30 
shown in Figs. 5b and 5c, respectively. It can be seen that both CA-Para matrix and 31 
CA-IBU matrix were designed and printed in a grid structure with the grid cell size of 32 
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500 × 500 µm2. The mean diameters of CA-Para fibers and CA-IBU fibers are 15.7 ± 1 
3.6 µm and 18.4 ± 4.8 µm, respectively. As shown in Figs. 5b’ and 5c’, both printed 2 
fibers were well aligned and stacked layer by layer precisely with uniform 3 
morphologies. This demonstrates the precision control via 3D EHD printing to 4 
manufacture patterned composite membranes.  5 
3.2. FTIR analysis of the composite membrane 6 
To confirm the stability of the compositions and the possible interactions between the 7 
materials of the composite membrane, FTIR analysis was performed (Fig. 6). For pure 8 
PCL, the characteristic absorption peaks at 2947 cm-1 and 1730 cm-1 are attributed to 9 
the asymmetric stretching of CH2 and carbonyl stretching, respectively [38]. The 10 
absorption peak at 1170 cm-1 is related to the stretching of –C-O [39]. These peaks can 11 
be identified in the composite membrane spectrum, confirming the presence of PCL in 12 
the composite membrane.  13 
For pure CA, the characteristic bands at 3495 cm-1, 1373 cm-1 and 1045 cm-1 are due to 14 
the -O-H group stretching, -C-CH3 group stretching and –C-O- bond stretching, 15 
respectively [40]. For pure IBU, the intense peak at 1720 cm-1 is assigned to the 16 
carbonyl (C=O) stretching [41], which is overlapping with PCL peak and can be seen 17 
in the composite membrane spectrum. The absorption bands at 1230 cm-1 and 937 cm-18 
1 are due to the stretching of C-C bond and rocking vibration of CH3 [42], respectively, 19 
which, although weak, can be found in the spectrum for composite membrane. For pure 20 
Para, the characteristic absorption peaks located at 3319 cm-1 and 1554 cm-1 are 21 
corresponding to –O-H group stretching and N-H group stretching, respectively [27]. 22 
All these characteristic peaks appear in the composite membrane spectrum, suggesting 23 
the presence of the drugs in the printed composite membrane. Hence, no additional 24 
peaks or peak changes were observed in the FTIR spectrum, indicating no physical 25 
incompatibilities between the components. 26 
3.3. DSC and XRD analysis of the composite membrane 27 
The DSC curves of pure PCL, CA, Para, IBU and the printed composite membrane are 28 
shown in Fig. 7a. An endothermal peak is present at 56.7 °C for pure PCL, indicating 29 
the melting point (Tm) of PCL [42]. For pure CA, the first endothermal peak at 67.5 °C 30 
and the second peak observed at 230.9 °C correspond to the glass transition temperature 31 
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(Tg) of CA, and the melting peak of CA is very close to the its Tg peak around 237 °C 1 
[43]. The DSC curve of pure Para shows a well-defined melting peak at 169.2 °C [3]. 2 
The sharp endothermic peak located at 77.2 °C corresponds to the melting temperature 3 
of pure IBU [44]. For the composite membrane, there are no significant changes in the 4 
melting peaks of the polymer PCL and CA, but a slight shift can be identified from 56.7 5 
°C to 51.1 °C for PCL and from 230.9 °C to 222.8 °C for CA. Besides, the endothermal 6 
peaks of Para and IBU cannot be seen in the DSC curve of the composite membrane, 7 
indicating the amorphous state of both drugs in the printed composite membrane. 8 
The XRD results further confirmed that both drugs were incorporated in the composite 9 
membrane in their amorphous forms. As shown in Fig. 7b, the sharp crystalline 10 
diffraction peaks of pure Para and IBU were not detectable in the XRD spectrum of the 11 
composite membrane because of their dispersion within the matrix material[18]. 12 
Although the drug loading was low, it was above the detection limits and can be 13 
successfully detected [12, 45, 46]. 14 
3.4. In vitro drug release test  15 
The release studies were performed in an acidic medium (gastric pH) for the first two 16 
hours then at intestinal pH (PBS) for 6 hours. As seen in Fig. 8, almost 100% of Para 17 
was released in the first 2 hours in the gastric medium. In contrast to Para release, IBU 18 
release was slower: almost 35% IBU was released during the gastric phase with 19 
subsequent sustained release in the intestinal phase. These different release behaviors 20 
may be due to the fact that Para is hydrophilic, and IBU is hydrophobic and weak acidic 21 
with poor solubility in the acidic media [47, 48]. Fig. 9 shows the SEM images of the 22 
three parts of the composite membranes after 8 h drug release test. It can be seen that 23 
CA-Para, central and CA-IBU components of composite membrane maintain their grid 24 
structures and show no obvious eroding or disintegrating. The magnified images in 25 
Figs. 9a’, 9b’ and 9c’ show that the surface morphologies of CA-Para, CA-IBU and 26 
central components were all uniform after drug release due to high polymer stability. 27 
The release mechanisms of Para and IBU from the composite membrane was 28 
investigated by fitting the release data to zero-order model, first-order model, Higuchi 29 
model and Korsmayer–Peppas mathematic model, as shown in Tab. 1. For Para release, 30 
it is best fitted by first order model with the highest correlation coefficient R2 = 0.9759 31 
[49]. IBU was best fitted by Higuchi kinetics with R2 value of 0.9928, indicating the 32 
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Fickian diffusion mechanism of IBU, which is further confirmed by Korsmeyer-Peppas 1 
modelling with n value of 0.5 [50]. 2 
The EE of IBU and Para were calculated to be 85.7 ± 7.2% and 87.9 ± 1.8%, 3 
respectively. Maximum EE is not obtained because drug partially diffuses from the 4 
semi-liquid polymer on the collector due to evaporation [51]. Moreover, the LC of IBU 5 
and Para were calculated to be 2.5 ± 0.3% and 1.3 ± 0.2%, respectively. The results 6 
indicate the feasibility of encapsulating drugs via 3D EHD printing. 7 
3.5. Magnetic property 8 
Magnetic nanoparticles (Fe3O4 NPs) could be added in the central component, by 9 
simply adding them to the printing solution, to further functionalize the composite 10 
membranes with magnetic properties. Vibration sample magnetometer (VSM) analysis 11 
was performed to quantify the magnetic properties of the composite membrane at a 12 
constant temperature (300 K). The hysteresis loop of the printed composite membrane 13 
in the field range between -10000 Oe and 10000 Oe is shown in Fig. 10a. The hysteresis 14 
loop shows a S-shaped curve with no remanence and coercivity, and the curve goes 15 
though the zero point. The saturation magnetization value of the composite membrane 16 
is 0.16 emu/g. Therefore, the results manifest the superparamagnetic nature of the 17 
printed composite membrane [52]. For better visualization, the magnetic property of 18 
the composite membrane was evaluated by a permanent magnet as shown in Fig. 10b. 19 
The composite membranes (in distilled water) were drawn to the attracting side by a 20 
magnet and was recovered after removal of the magnet. The magnetic composite 21 
membranes may have many potential applications such as (but not limited to) magnetic 22 
targeting, visualization in MRI and magnetic heating [53, 54]. 23 
3.6. Biocompatibility analysis 24 
PCL and CA are FDA approved materials which are widely used in the pharmaceutical 25 
industry [55, 56]. However, it is still necessary to investigate the biocompatibility of 26 
the composite membranes, due to the potential toxicity of actives and solvents used 27 
during the preparation procedures. Herein, L929 cells were cultured on the composite 28 
membrane for 3 days. The morphologies of L929 cells were observed through 29 
fluorescence microscope as shown in Fig. 11. Figs. 11a, 11b and 11c display the merged 30 
fluorescent images of cells growing on the CA-IBU part, CA-Para part and the central 31 
14 
 
component, respectively. Figs. 11a’, 11b’ and 11c’ are the magnified images of Figs. 1 
11a, 11b and 11c, respectively, showing the detailed cell morphology on the composite 2 
membrane. From the inserts of bright field images, it can be seen that cells grew well 3 
with the composite membranes, highlighting the good biocompatibility of the 4 
composite membranes. 5 
 6 
4. Conclusion 7 
In summary, multi-drug-loaded composite membranes consisting of the drug-loaded 8 
parts and intermediate folding section were prepared via 3D EHD printing successfully. 9 
The composite membrane found to deliver two drugs with well-defined drug release 10 
mechanisms. IBU and Para were respectively loaded in two different CA films in their 11 
amorphous forms, and linked by the PCL folding layer for the treatmemt of fever or 12 
pain alleviation. The mechanical property and unfolding property of the composite 13 
membranes were controllable by regulating the layer number of the folding layer. The 14 
composite membranes were able to be folded and capsulated into capsules for ease of 15 
swallowing, and re-spread out during drug release process. The magnetic property of 16 
the composite membrane can be obtained by adding magnetic NPs into the middle PCL 17 
layer for targeting applications. The good biocompatibility of the composite membrane 18 
was proved via L929 cell culture experiments. These composite membranes were 19 
controllable and flexible, and possess potential applications in drug combination 20 
therapy and personalized medicine. 21 
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Table and Figure Captions 2 
Tables 3 
Table 1. Fitting parameters of Para and IBU release from the composite membrane. 4 
 5 
Figures 6 
Figure 1. (a) The schematic of the 3D EHD printing set-up. (b) Image of  stable printing 7 
cone. (c) The design of the composite membrane, consisting of two drug loaded parts 8 
(CA-IBU and CA-Para) and a central component (PCL-Fe3O4 NPs). 9 
Figure 2. Photographs of printed composite membranes with different layers of folding 10 
part (P5, P10 and P20) with a scale of 10 mm. 11 
Figure 3. (a) Stress-strain curves of different printed composite membranes (P5, P10 12 
and P20), the inserts show the images of P5, P10 and P20 after tension tests with a scale 13 
of 10 mm. (b) Maximum stress and Maximum strain of P5, P10 and P20. 14 
Figure 4. The unfolding study of different composite membranes (P5, P10 and P20): 15 
(a) unfolding angles and images of P5, P10 and P20 after 15 minutes’ standing; (b) 16 
unfolding angles and images of P5, P10 and P20 after 15 minutes’ oscillation. 17 
Figure 5. SEM images of the composite membrane and the diameter distribution 18 
graphs: (a) Central component with 10 layers; (b) CA-Para part with 10 layers; (c) CA-19 
IBU part with 10 layers. (a’), (b’) and (c’) are magnified images of (a), (b) and (c), 20 
respectively. 21 
Figure 6. FTIR spectra of pure PCL, CA, Para, IBU and the composite membrane. 22 
Figure 7. (a) DSC curves of pure PCL, CA, Para, IBU and the composite membrane. 23 
(b) XRD patterns of pure PCL, CA, Para, IBU and the composite membrane. 24 
Figure 8. Drug release profiles of Para and IBU from the composite membrane in the 25 
simulated gastrointestinal tract. 26 
Figure 9. SEM images of the composite membrane after 8h drug release: (a) central 27 
18 
 
component; (b) CA-Para part; (c) CA-IBU part. (a’), (b’) and (c’) are magnified images 1 
of (a), (b) and (c), respectively. 2 
Figure 10. (a) Magnetic curves of the composite membrane. (b) Composite membranes 3 
response to an externally applied magnetic source. 4 
Figure 11. Fluorescent micrographs of L929 cells with the composite membrane: (a) 5 
CA-IBU part; (b) CA-Para part; (c) Central component. (a’), (b’) and (c’) are magnified 6 
images of (a), (b) and (c), respectively. Inserts in (a’), (b’) and (c’) are bright field 7 
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